- Home
- PFO vs ELUT Comparison
PFO vs ELUT Comparison
Compare PFO & ELUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PFO | ELUT |
|---|---|---|
| Founded | 1991 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 117.3M | 45.8M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | PFO | ELUT |
|---|---|---|
| Price | $8.88 | $1.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 32.5K | ★ 154.3K |
| Earning Date | 01-01-0001 | 03-11-2026 |
| Dividend Yield | ★ 6.51% | N/A |
| EPS Growth | N/A | ★ 146.77 |
| EPS | N/A | ★ 0.87 |
| Revenue | N/A | ★ $12,293,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $10.83 |
| P/E Ratio | ★ N/A | $1.21 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.01 | $0.50 |
| 52 Week High | $9.90 | $2.99 |
Technical Indicators
Market Signals| Indicator | PFO | ELUT |
|---|---|---|
| Relative Strength Index (RSI) | 21.67 | 48.02 |
| Support Level | N/A | $0.86 |
| Resistance Level | $9.76 | $1.16 |
| Average True Range (ATR) | 0.10 | 0.09 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 6.90 | 21.54 |
Price Performance
Historical ComparisonAbout PFO Flaherty & Crumrine Preferred and Income Opportunity Fund Incorporated
Flaherty & Crumrine Prfd Income Oppo is the United States-based diversified, closed-end management investment company. Its primary investment objective is to provide its common shareholders with high current income consistent with the preservation of capital. The fund invests in a diversified portfolio of preferred securities which includes traditional preferred stocks eligible for the inter-corporate dividends received a deduction and fully taxable preferred securities.
About ELUT Elutia Inc.
Elutia Inc develops proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients. Its products include CanGaroo, designed for implantable electronic devices, and SimpliDerm, used in soft tissue repair, with functions related to implant support and wound management. The company operates in two segments: Women's Health and Cardiovascular. The majority of revenue is derived from the Women's Health segment.